HRP20121045T1 - Farmaceutska smjesa za parenteralnu primjenu antagonista beta-adrenoreceptora ultrakratkog djelovanja - Google Patents
Farmaceutska smjesa za parenteralnu primjenu antagonista beta-adrenoreceptora ultrakratkog djelovanja Download PDFInfo
- Publication number
- HRP20121045T1 HRP20121045T1 HRP20121045AT HRP20121045T HRP20121045T1 HR P20121045 T1 HRP20121045 T1 HR P20121045T1 HR P20121045A T HRP20121045A T HR P20121045AT HR P20121045 T HRP20121045 T HR P20121045T HR P20121045 T1 HRP20121045 T1 HR P20121045T1
- Authority
- HR
- Croatia
- Prior art keywords
- cyclodextrin
- solution containing
- salt
- flestolol
- landiolol
- Prior art date
Links
- 229940121840 Beta adrenoreceptor antagonist Drugs 0.000 title claims 5
- 238000007911 parenteral administration Methods 0.000 title claims 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 19
- 239000000243 solution Substances 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 13
- 229920000858 Cyclodextrin Polymers 0.000 claims 11
- ZPLOQFLCMVIWRY-UHFFFAOYSA-N flestolol Chemical compound NC(=O)NCC(C)(C)NCC(O)COC(=O)C1=CC=CC=C1F ZPLOQFLCMVIWRY-UHFFFAOYSA-N 0.000 claims 10
- 229950001315 flestolol Drugs 0.000 claims 10
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 claims 9
- 229960003745 esmolol Drugs 0.000 claims 9
- WMDSZGFJQKSLLH-RBBKRZOGSA-N landiolol Chemical compound O1C(C)(C)OC[C@H]1COC(=O)CCC(C=C1)=CC=C1OC[C@@H](O)CNCCNC(=O)N1CCOCC1 WMDSZGFJQKSLLH-RBBKRZOGSA-N 0.000 claims 9
- 229950005241 landiolol Drugs 0.000 claims 9
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 5
- 239000001116 FEMA 4028 Substances 0.000 claims 4
- 208000001871 Tachycardia Diseases 0.000 claims 4
- 229960004853 betadex Drugs 0.000 claims 4
- 230000006794 tachycardia Effects 0.000 claims 4
- -1 2-hydroxypropyl Chemical group 0.000 claims 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000007888 Sinus Tachycardia Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 210000001992 atrioventricular node Anatomy 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 210000005242 cardiac chamber Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Uporaba ciklodekstrina i/ili funkcionalnog derivata ciklodekstrina izabranog iz grupe koja obuhvaća α-ciklodekstrin, β-ciklodekstrin, γ-ciklodekstrin, (2-hidroksipropil)-β-ciklodekstrin i (sulfobutileter)-7β-ciklodekstrin i njihove smjese, za povećanje stabilnosti antagonista β-adrenoreceptora ultrakratkog djelovanja izabranog iz grupe koja obuhvaća esmolol, landiolol, flestolol ili njegovu farmaceutski prihvatljivu sol, u vodenoj otopini stabilnoj za čuvanje za parenteralnu primjenu.
2. Farmaceutska smjesa za parenteralnu primjenu antagonista β-adrenoreceptora ultrakratkog djelovanja u obliku otopine stabilne za čuvanje, koja u biti sadrži
a) antagonist β-adrenoreceptora ultrakratkog djelovanja izabran iz grupe koja obuhvaća esmolol, landiolol, flestolol ili njegovu farmaceutski prihvatljivu sol,
b) vodu,
c) ciklodekstrina i/ili funkcionalni derivat ciklodekstrina izabran iz grupe koja obuhvaća α-ciklodekstrin, β-ciklodekstrin, γ-ciklodekstrin, (2-hidroksipropil)-β-ciklodekstrin i (sulfobutileter)-7β-ciklodekstrin.
3. Farmaceutska smjesa prema zahtjevu 2, sadrži druge pomoćne tvari izabrane između pufera, konzervansa, otapala koja se miješaju s vodom, soli, šećernih alkohola i/ili šećera.
4. Uporaba smjese prema bilo kojem od zahtjeva 1 do 3, naznačeno time što je pH vrijednost te otopine 3 do 7.5, poželjno 5 do 7.
5. Uporaba smjese prema bilo kojem od zahtjeva 1 do 4, naznačeno time što je koncentracija ciklodekstrina, odnosno njegovog funkcionalnog derivata, 0.1% do 20% (w/v), poželjno 0.25% do 7% (w/v), posebno poželjno 0.5% do 4%.
6. Uporaba ili smjesa prema bilo kojem od prethodnih zahtjeva, naznačeno time što je koncentracija antagonista β-adrenoreceptora ultrakratkog djelovanja, odnosno njegove soli, 0.1% do 30%.
7. Uporaba ili smjesa prema bilo kojem od prethodnih zahtjeva, naznačeno time što je osmolalnost otopine 270 mosmol/l do 310 mosmol/l, poželjno 280 mosmol/l do 300 mosmol/l.
8. Uporaba ili smjesa prema bilo kojem od prethodnih zahtjeva, gdje je ta smjesa prisutna u obliku prodajne jedinice izabrane iz grupe koja obuhvaća- 1 ml otopine koja sadrži 10-20 mg esmolola ili njegove soli - 2 ml otopine koja sadrži 10-100 mg esmolola ili njegove soli - 5 ml otopine koja sadrži 50-500 mg esmolola ili njegove soli - 10 ml otopine koja sadrži 50-5000 mg, posebno 2500 mg esmolola ili njegove soli - 50 ml otopine koja sadrži 50-5000 mg esmolola ili njegove soli - 100 ml otopine koja sadrži 50-5000 mg esmolola ili njegove soli - 250 ml otopine koja sadrži 50-5000 mg esmolola ili njegove soli.
9. Uporaba ili smjesa prema bilo kojem od zahtjeva 1 do 8, gdje je ta smjesa prisutna u obliku prodajne jedinice izabrane iz grupe koja obuhvaća- 1 ml otopine koja sadrži 5-20 mg landialola ili flestolola ili njegove soli - 2 ml otopine koja sadrži 5-100 mg landiolola ili flestolola ili njegove soli- 5 ml otopine koja sadrži 10-500 mg landiolola ili flestolola ili njegove soli - 10 ml otopine koja sadrži 10-5000 mg landiolola ili flestolola ili njegove soli - 25 ml otopine koja sadrži 25-2500 mg landiolola ili flestolola ili njegove soli- 50 ml otopine koja sadrži 50-5000 mg landiolola ili flestolola ili njegove soli - 100 ml otopine koja sadrži 50-5000 mg landiolola ili flestolola ili njegove soli - 250 ml otopine koja sadrži 50-5000 mg landiolola ili flestolola ili njegove soli.
10. Uporaba smjese prema bilo kojem od prethodnih zahtjeva za proizvodnju lijeka za snižavanje frekvencije srčanih klijetki u bolesnika s atrijskom fibrilacijom, atrijskom undulacijom i sinusnom tahikardijom, s atrioventrikularnom tahikardijom i tahikardijom AV čvora, s tahikardijalnim supra i ventrikularnim aritmijama, s tahikardijom i/ili hipertenzijom prije, tijekom i nakon operacija kao i u drugim hitnim slučajevima, za profilaksu i liječenje perioperativnih ishemija, za liječenje nestabilne angine pektoris i akutnog infarkta miokarda.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT21072007 | 2007-12-21 | ||
| PCT/AT2008/000470 WO2009079679A2 (de) | 2007-12-21 | 2008-12-22 | Pharmazeutische zusammensetzung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20121045T1 true HRP20121045T1 (hr) | 2013-01-31 |
Family
ID=40634349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20121045AT HRP20121045T1 (hr) | 2007-12-21 | 2012-12-18 | Farmaceutska smjesa za parenteralnu primjenu antagonista beta-adrenoreceptora ultrakratkog djelovanja |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20100311738A1 (hr) |
| EP (1) | EP2234614B1 (hr) |
| JP (1) | JP5623288B2 (hr) |
| CN (1) | CN101903024A (hr) |
| AU (1) | AU2008340179B2 (hr) |
| CA (1) | CA2712414C (hr) |
| CY (1) | CY1114951T1 (hr) |
| DK (1) | DK2234614T3 (hr) |
| ES (1) | ES2397126T3 (hr) |
| HR (1) | HRP20121045T1 (hr) |
| NZ (1) | NZ586200A (hr) |
| PL (1) | PL2234614T3 (hr) |
| PT (1) | PT2234614E (hr) |
| SI (1) | SI2234614T1 (hr) |
| WO (1) | WO2009079679A2 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2872953C (en) | 2012-05-10 | 2020-04-07 | Aop Orphan Pharmaceuticals Ag | Parenteral esmolol formulation |
| EP2796139A1 (en) * | 2013-04-26 | 2014-10-29 | AOP Orphan Pharmaceuticals AG | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985004580A1 (en) * | 1984-04-09 | 1985-10-24 | American Hospital Supply Corporation | Pharmaceutical composition and method for treatment or prophylaxis of cardiac disorders |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4857552A (en) | 1988-06-08 | 1989-08-15 | E. I. Du Pont De Nemours And Co. | Stable pharmaceutical composition |
| DE4207922A1 (de) | 1992-03-13 | 1993-09-23 | Pharmatech Gmbh | Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung |
| CA2150554A1 (en) * | 1992-12-02 | 1994-06-09 | Sheng-Wan Tsao | Cyclodextrin and polymer based drug delivery system |
| EP1239864A1 (en) | 1999-11-23 | 2002-09-18 | Aderis Pharmaceuticals, Inc. | Treatment of heart rhythm disturbances with n6 -substituted-5'-(n-substituted) carboxamidoadenosines |
| TWI277414B (en) * | 2001-01-12 | 2007-04-01 | Baxter Int | Esmolol formulation |
| WO2003028718A1 (en) * | 2001-10-01 | 2003-04-10 | Smithkline Beecham Corporation | Novel formulations of carvedilol |
| WO2003033025A2 (en) | 2001-10-18 | 2003-04-24 | Decode Genetics Ehf | Cyclodextrin complexes |
| JP2005530736A (ja) * | 2002-04-18 | 2005-10-13 | シーブイ・セラピューティクス・インコーポレイテッド | ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にａ１アデノシンアゴニストを投与することを含む不整脈の処置方法 |
| US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
| EP1417962A1 (de) | 2002-11-06 | 2004-05-12 | AOP Orphan Pharmaceuticals AG | Verfahren zur Herstellung eines Arzneimittels enthaltend Esmolol |
| US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| CN1827109A (zh) * | 2006-04-14 | 2006-09-06 | 北京润德康医药技术有限公司 | 一种以兰洛地尔及其盐为活性成分的冻干粉针制剂及其制备工艺 |
| US8722736B2 (en) * | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
-
2008
- 2008-12-22 PT PT88638309T patent/PT2234614E/pt unknown
- 2008-12-22 US US12/809,927 patent/US20100311738A1/en not_active Abandoned
- 2008-12-22 ES ES08863830T patent/ES2397126T3/es active Active
- 2008-12-22 EP EP08863830A patent/EP2234614B1/de active Active
- 2008-12-22 CA CA2712414A patent/CA2712414C/en active Active
- 2008-12-22 JP JP2010538268A patent/JP5623288B2/ja active Active
- 2008-12-22 NZ NZ586200A patent/NZ586200A/en unknown
- 2008-12-22 WO PCT/AT2008/000470 patent/WO2009079679A2/de active Application Filing
- 2008-12-22 SI SI200830850T patent/SI2234614T1/sl unknown
- 2008-12-22 AU AU2008340179A patent/AU2008340179B2/en active Active
- 2008-12-22 DK DK08863830.9T patent/DK2234614T3/da active
- 2008-12-22 CN CN200880122163XA patent/CN101903024A/zh active Pending
- 2008-12-22 PL PL08863830T patent/PL2234614T3/pl unknown
-
2012
- 2012-12-18 HR HRP20121045AT patent/HRP20121045T1/hr unknown
- 2012-12-20 CY CY20121101243T patent/CY1114951T1/el unknown
-
2016
- 2016-08-26 US US15/248,845 patent/US20160361422A1/en not_active Abandoned
-
2018
- 2018-10-19 US US16/164,926 patent/US10660964B2/en active Active
-
2020
- 2020-04-28 US US16/860,336 patent/US11517624B2/en active Active
-
2022
- 2022-12-05 US US18/061,562 patent/US20230277674A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20230277674A1 (en) | 2023-09-07 |
| WO2009079679A2 (de) | 2009-07-02 |
| US11517624B2 (en) | 2022-12-06 |
| ES2397126T3 (es) | 2013-03-04 |
| AU2008340179A1 (en) | 2009-07-02 |
| CA2712414A1 (en) | 2009-07-02 |
| US20200323988A1 (en) | 2020-10-15 |
| PL2234614T3 (pl) | 2013-03-29 |
| SI2234614T1 (sl) | 2013-01-31 |
| US20160361422A1 (en) | 2016-12-15 |
| US10660964B2 (en) | 2020-05-26 |
| CN101903024A (zh) | 2010-12-01 |
| US20190046646A1 (en) | 2019-02-14 |
| US20100311738A1 (en) | 2010-12-09 |
| CY1114951T1 (el) | 2016-12-14 |
| JP2011506486A (ja) | 2011-03-03 |
| AU2008340179B2 (en) | 2014-10-23 |
| EP2234614A2 (de) | 2010-10-06 |
| CA2712414C (en) | 2016-07-12 |
| JP5623288B2 (ja) | 2014-11-12 |
| DK2234614T3 (da) | 2013-02-11 |
| EP2234614B1 (de) | 2012-10-17 |
| NZ586200A (en) | 2012-06-29 |
| PT2234614E (pt) | 2013-01-25 |
| WO2009079679A3 (de) | 2009-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10512697B2 (en) | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | |
| CA2401424C (en) | Alprazolam inclusion complexes and pharmaceutical compositions thereof | |
| Loftsson et al. | Enalaprilat and enalapril maleate eyedrops lower intraocular pressure in rabbits | |
| HUE027551T2 (en) | Compositions containing amiodarone and cyclodextrin sulfoalkyl ester | |
| US20230277674A1 (en) | Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists | |
| JPH08506119A (ja) | 認識活性化剤ＣＩ−９７９ＨＣ▲ｌ▼の中性安定化複合体 | |
| AR066168A1 (es) | Formulaciones galenicas de compuestos organicos | |
| WO2007059507A3 (en) | Compositions comprising lipoxygenase inhibitors and cyclodextrin | |
| JP2011506486A5 (hr) | ||
| WO2006113310A3 (en) | Nanoparticulate and controlled release compositions comprising prostaglandin derivatives | |
| CN114845701A (zh) | 1-(5-(2,4-二氟苯基)-1-((3-氟苯基)磺酰基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺的液体药物组合物 | |
| HRP20231337T1 (hr) | Vodena formulacija koja sadrži 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureu | |
| AR073384A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno y amlodipina, y metodo de preparacion | |
| AU2015255164B2 (en) | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | |
| JP4275394B2 (ja) | 注射用シロスタゾール水性製剤 | |
| JP2005527615A5 (hr) | ||
| JP2006117704A5 (hr) | ||
| ZA200207221B (en) | Alprazolam inclusion complexes and pharmaceutical compositions thereof. | |
| JP2005527615A (ja) | ナトリウムチャンネルブロッカーの非経口適用のための新規な製剤 |